Characteristics of Glargine in Type 2 Diabetics

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

January 31, 2010

Conditions
Type 2 Diabetes
Interventions
DRUG

Placebo

single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours

DRUG

Insulin Glargine 0.5 u/kg body wt SC

8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)

DRUG

Insulin Glargine 1.0 u/kg body wt SC

DRUG

Insulin Glargine 1.5 u/kg body wt SC

DRUG

Insulin Glargine 2.0 u/kg body wt SC

Trial Locations (1)

37232

Vanderbilt University, Nashville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER

NCT00574912 - Characteristics of Glargine in Type 2 Diabetics | Biotech Hunter | Biotech Hunter